Uniklinik Köln
- Address
- Kerpener Straße 62, 50937 Cologne, Germany
Nervous System Diseases
At Uniklinik Köln the Neurology department focuses on neurodegenerative conditions, particularly Alzheimer's Disease, aiming to assess the safety and tolerability of new therapeutic agents.
- Safety and tolerability assessment of a selective muscarinic M1 agonist
- Exploratory evaluation of cognitive benefits in mild to moderate disease
- Integration of patient‑reported outcomes for early‑stage dementia
These investigations seek to expand treatment options for individuals with early‑stage dementia while ensuring a strong safety profile.
Virus Diseases
Research on viral complications after organ transplantation includes investigation of BK Polyomavirus DNAemia in kidney transplant recipients.
- Monitoring of viral load dynamics post‑transplant
- Evaluation of immunosuppression steering based on virus‑specific T‑cell levels
- Assessment of graft function and infection‑related outcomes
The aim is to refine post‑transplant care by balancing antiviral control with immunosuppressive therapy to protect kidney function.
Immune system processes
The site explores immune system processes that influence both neurodegeneration and transplant outcomes, linking immune modulation to disease progression.
- Role of virus‑specific CD4 T cells in controlling infection
- Interaction between immunosuppression strategies and neuroinflammatory pathways
- Development of biomarkers to predict therapeutic response
Gaining insight into these mechanisms may enable personalized approaches that improve efficacy while reducing adverse effects across multiple therapeutic areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1Nsc Therapeutics GmbH1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniklinik Köln
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Immunosuppression Management Using BK Polyomavirus-Specific T Cells in BKPyV DNAemia Post-Kidney Transplantation with Prednisolone and Drug Combination | Paediatrisches Forschungsnetzwerk gGmbH, PROFIL Institut fuer Stoffwechselforschung GmbH | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| (S)-2-ETHYL-8-METHYL-1-THIA-4,8-DIAZASPIRO[4.5]DECAN-3-ONE | 1 | Unknown | 2025-08-25 | 2025-08-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.